Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

More Disappointing Results with EGFR/COX-2 Combination
Author
Howard (Jack) West, MD

When I first started OncTalk, there was a lot of buzz about celebrex (celecoxib) as a cancer drug, but almost all of it was among patients talking about it on the internet: oncologists watching the field hadn't been impressed by the early returns, including this one (despite the fact that some of my earliest work in lung cancer was on cyclo-oxygenase-2, or COX-2, the target of celebrex). I must admit that part of the idea of me providing commentary here was to provide a filter and a dose of healthy skepticism to keep people from being swept up by a tide of irrational exuberance about an unproven and largely untested drugs and approaches. Just over a year ago, I wrote a prior post about studies combining EGFR inhbitors like iressa (gefitinib) and tarceva (erlotinib) with celebrex or vioxx (rofecoxib); I wasn't very impressed, overall, although some early work by Dr. Karen Reckamp at City of Hope Cancer Center looked promising, with more work combining tarceva and celebrex ongoing.

But another article was published (abstract here) on the combination of celebrex (at a pretty high dose of 400 mg twice daily) and iressa (at a typical dose of 250 mg daily) as a first line therapy for advanced NSCLC, in an unselected population (not chosen by smoking status, EGFR mutations, COX-2 protein expression on the tumor, etc.). This study was conducted by the Hoosier Oncology Group (affectionately known as HOG) in Indiana, who enrolled 31 patients. They found that there was certainly activity, but the response rate of 16% and median survival of 7 months was on the low side for what you'd expect in a group of patients with advanced NSCLC who started with the standard approach of platinum-based doublet chemo (with or without avastin). Another concerning issue was that 2 of these 31 patients developed fatal interstitial pneumonitis, and inflammation of the lungs, a complication that can rarely occur with EGFR inhibitors, but I've never had a life-threatening or fatal case occur in the well over 200 patients I've treated with iressa or tarceva in the past 5-6 years, so having this occur in 2 of 31 patients, or 6%, is pretty concerning for the possibility that there is a danger to this combination.

It's possible that the results would have been better if they only enrolled patients who never smoked, or who had EGFR mutations or high expression of the COX-2 protein on their tumors. We can't say that this combination wouldn't be good for anyone, but this trial was a clear disappointment to the investigators and corroborates my belief that there is definitely no reason to deliberately combine these drugs in hopes of improving the impact as a lung cancer treatment outside of a clinical trial.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on